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Introduction: Against the backdrop of increasing resistance to conventional antibiotics, 45 
bacteriocins represent an attractive alternative, given their potent activity, novel modes of 46 
action and perceived lack of issues with resistance. 47 
Aim: In this study, the nature of the antibacterial activity of a clinical isolate of 48 
Streptococcus gallolyticus was investigated. 49 
Methods: Optimisation of the production of an inhibitor from strain AB39 was performed 50 
using different broth media and supplements. Purification was carried out using size 51 
exclusion, ion exchange and high-pressure liquid chromatography (HPLC). Gel diffusion 52 
agar overlay, MS/MS, de-novo peptide sequencing and genome mining were utilised in a 53 
proteogenomic approach to facilitate identification of the genetic basis for production of the 54 
inhibitor. 55 
Results: Strain AB39 was identified as Streptococcus gallolyticus subsp pasteurianus and 56 
the successful production and purification of the AB39 peptide, named nisin P, with a mass 57 
of 3,133.78 Da, was achieved using BHI broth with 10% serum. Nisin P showed anti-58 
bacterial activity towards clinical isolates of drug resistant bacteria, including MRSA, VRE 59 
and penicillin resistant Streptococcus pneumoniae. In addition, the peptide exhibited 60 
significant stability towards high temperature, wide pH and certain proteolytic enzymes and 61 
displayed very low toxicity towards sheep red blood cells and Vero cells. 62 
Conclusion: To the best of our knowledge, this is the first production, purification and 63 
characterisation of nisin P. Further study of nisin P may reveal its potential for treating or 64 
preventing infections caused by antibiotic resistant Gram positive bacteria, or those 65 
evading vaccination regimens. 66 
 67 
Introduction  68 
Antimicrobial resistance (AMR) is widely stated by various international authorities and 69 
agencies as one of the leading global threats to human health. Many measures are 70 
required for controlling the AMR crisis, including searching for novel antibiotic drugs that 71 
potentially work with a new mode of action (1-6). The majority of antibiotics in clinical use 72 
were discovered being naturally produced by environmental microorganisms (7, 8), which 73 
could serve as the source of alternative antimicrobial approaches. Bacteriocins are gaining 74 
interest as one such alternative approach, due to a number of favourable properties, 75 
although a lack of research has been conducted compared with that carried out on 76 
conventional antibiotics (1, 9).  77 
Bacteriocins are naturally produced ’’ribosomally synthesised’’ toxins found in many strains 78 
of bacteria and certain Archaea. They have activity towards other multidrug resistant 79 
pathogenic bacteria have and been considered as promising candidates for replacing 80 
traditional antibiotics (10-14). Approximately 99% of all bacterial strains are capable of 81 
producing at least one bacteriocin (15) however, without optimisation, most bacteria will 82 
not express bacteriocins under normal laboratory conditions (16, 17). Bacteriocins either 83 
exhibit a narrow spectrum of activity towards strains closely-related to the producer or a 84 
border spectrum of activity by targeting various species of Gram-positive and negative 85 
bacteria, viruses, fungi, parasites or even tumour cells (13, 18-20). Due to the safe long 86 
utilise of certain bacteriocins and their producing bacterial ‘‘probiotic’’ strains, particularly 87 
lactic acid producing bacteria (LAB) and their anti-bacterial products (e.g nisin-A), they 88 
have been considered as Generally Regarded as Safe (GRAS) and their producers 89 
possess Qualified Presumption of Safety (QPS) status (21). Due to the fact that 90 
bacteriocins and their producing bacteria possess certain coveted features, such as broad 91 
spectrum, high potency, stability to pyrolytic enzymes and limited toxicity towards targeted 92 
hosts, they have become attractive candidates and are the focus of much research in 93 
human and animal health, food preservation and agriculture (17, 21-26).  94 
Gram positive pathogens are still a major problem in human health, particularly drug 95 
resistant strains (27), emphasising the need for the discovery of novel biological agents 96 
targeting this group of bacteria. This study focuses on a strain of Streptococcus 97 
gallolyticus, a species originally described as Streptococcus bovis. A small number of 98 
bacteriocins have been identified from various strains S. bovis of this bacterium, including 99 
Bovicin HC5, Bovicin 255, Bovicin HJ50 and macedocin ST91KM (28-33).  100 
In this project, and to the best of our knowledge, this is the first report of the production, 101 
physicochemical characterisation and evaluation of toxicity of a nisin related antibacterial 102 
inhibitor (nisin P), produced by S. gallolyticus subsp pasteurianus, formerly known as S. 103 
bovis biotype II/2 (34). Nisin P exhibits a spectrum of activity towards drug resistant 104 
clinically relevant Gram positive pathogenic bacteria including MRSA, VRE and drug 105 
resistant S. pneumoniae with very limited toxicity towards sheep erythrocytes and monkey 106 
kidney epithelial cells [Vero cells]. Interestingly, nisin P did not show activity towards 107 
breast adenocarcinoma [MCF_7] and liver hepatocellular carcinoma [HepG2] cells, 108 
although other nisin variants (nisin A & nisin Z) have been reported for their activity 109 
towards these malignancies (35-39). 110 
 111 
Materials and Methods 112 
Collection of isolates and antimicrobial screening  113 
Strain AB39 was identified in a collection of bacterial strains that had been co-isolated with 114 
Escherichia coli from suspected urinary tract infections. Samples were obtained at the 115 
University of Plymouth NHS Trust Hospital, Plymouth, UK in 2016. Antimicrobial activity 116 
was revealed by screening against Micrococcus luteus [Strain-1.1-University of Plymouth 117 
(UoP)] Staph. aureus (NCTC 12981), S. pneumoniae (NCTC 12695), Escherichia coli 118 
(DH5α) and Klebsiella pneumoniae (NCTC 9633). Initial detection of antagonistic strains 119 
was obtained via simultaneous antagonistic assays (40). Columbia Blood agar (CBA) 120 
plates (Oxoid) were used for culturing bacteria in an aerobic atmosphere supplemented 121 
with 5% CO2 at 37°C. Strain AB39 was chosen for detailed investigation due to the 122 
absence of haemolytic activity on CBA and activity toward drug resistant clinical strains. A 123 
spot-on-lawn assay with certain modifications (41) and well diffusion assays (42) were 124 
used to track active fractions of the peptide during various steps of optimisation and 125 
purification. M. luteus bacterium was used throughout all steps of the purification and 126 
characterisation.  127 
 128 
Optimising bacteriocin production 129 
An extensive range of broth media, growth conditions and incubation times were utilised to 130 
obtain the highest yield of the produced peptide. To determine the best medium and 131 
growth conditions leading to high yield of the peptide, a 2-fold dilution was carried out 132 
using culture supernatants from each medium and growth condition used. This was 133 
subjected to a spot-on-lawn assay (41) and all observed inhibitory zones were measured 134 
using the following formula: AU/ml = (reciprocal of the highest active dilution) / (volume of 135 
the sample) X 1000 (43). This experiment was carried out in triplicate.  136 
 137 
Purification of the antibacterial peptide 138 
S. gallolyticus grown in BHI (Oxoid) plus 10% serum (Gibco™ Life Technologies, UK) 139 
was centrifuged at 7400 g for 20-30 minutes and the supernatant was subjected to 140 
preliminary purification using Strata® C18-E columns (Phenomenex® Ltd., Macclesfield, 141 
UK). Fractions of the AB39 inhibitor were eluted using acidified (pH2) methanol (MeOH; 142 
Fisher Scientific, Loughborough, UK) at 30%, 50% 70%, 80% and 90% concentrations. 143 
MeOH was then evaporated from all active fractions using a rotary evaporator 144 
(LABOROTA (4001) Heidolph, Schwabach, Germany), which were then combined and 145 
run into a C18 Sep-Pak® Plus column (Waters Corporation, Milford, Massachusetts, 146 
USA) with 2.5% increments of Acetonitrile [(ACN) Fisher-Scientific] used for elution of 147 
AB39 peptide. ACN from active fractions was evaporated using the Biotage® V-10 148 
Touch evaporation system (Biotage, Uppsala Sweden), followed by Reverse Phase 149 
High Pressure Liquid Chromatography (RP-HPLC) [250 × 10 mm C18 column (Agilent, 150 
Edinburgh, UK)] using a Gilson HPLC purification system (Gilson, Dunstable, UK). 151 
Fractions were collected via an automated collector and a gradient of 10-90% ACN at a 152 
flow rate of 0.5 column volumes (CV) per minute. An activity-based tracking system via 153 
the spot assay was applied during all steps of purification. Purified nisin P was tested 154 
against various species of Gram positive and -negative bacteria. 155 
SDS-PAGE and gel diffusion agar overlay   156 
Purified fractions of the AB39 peptide were run into an SDS-PAGE gel (Bolt™ Mini Gels; 157 
Invitrogen™, Life Technologies, Warrington, UK) following the manufacture’s 158 
instructions. Aliquots (10 µl) of a pre-stained protein standard (See Blue® Plus2; Life 159 
Technologies) and the prepared sample were loaded into designated wells and the gel 160 
run at 165 volts for 32 minutes followed by staining with Instant Blue stain (Expedeon 161 
Ltd, Cambridge, UK) for 30-60 minutes. SDS-gels were then washed multiple times with 162 
ultra-pure water, minimally for 4 hours. Individual lanes were excised as strips and 163 
placed aseptically onto a Nutrient Agar (NA) plate. Molten sterile NA was seeded at 164 
~45°C with M. luteus at a suspension equivalent to a 0.5 McFarland standard that had 165 
been diluted to 1:100 (44). This was poured over the gel strip and incubated aerobically 166 
at 37oC overnight followed by observation of any zones of inhibition in the lawn.  167 
Liquid chromatography–mass spectrometry (LCMS) and de-novo peptide 168 
sequencing 169 
Filter Aided Sample Preparation (FASP) was conducted on active fractions from HPLC, 170 
followed by digestion using LysC (45). The digested sample was then cleaned and 171 
desalted via the StageTip technique (45) and concentrated samples were transferred into 172 
glass micro-vials ready for MS/MS analysis. Peptides were separated on a Dionex 173 
Ultimate 3000 RSLC nano flow system (Dionex, Camberly UK). A 3 μl of sample was 174 
loaded in 0.1% trifluoroacetic acid (TFA) and acetonitrile (2% acetonitrile in 0.1% TFA) 175 
onto an Acclaim Pep Map100 μm × 2 cm, 3 μm C18 nano trap column, at a flow rate of 5 176 
μl/min, bypassing the analytical column. Elution of bound peptides was performed with the 177 
trap column inline with an Acclaim PepMap C18 nano column 75 μm × 25 cm, 3 μm, 100 Å 178 
(Analytical Column) with a linear gradient of 96% buffer A and 4% buffer B to 60% buffer A 179 
and 40% buffer B, (Buffer A: 0.5% Acetic Acid, Buffer B: 80% acetonitrile in 0.5% acetic 180 
acid) at a constant flow rate of 300nl/min over 60 minutes. The sample was ionized in 181 
positive ion mode using a Proxeon nano spray ESI source (Thermo Fisher Hemel UK) and 182 
analyzed in an Orbitrap Velos Pro FTMS (Thermo Finnigan, Bremen, Germany). The 183 
Orbitrap Velos Pro instrument underXcalibur2.1 software was operated in the data 184 
dependent mode to automatically switch between MS and MS/MS acquisition.  MS spectra 185 
of intact peptides (m/z 350-1600) with an automated gain control accumulation target 186 
value of 1000000 ions were acquired with a resolution of 60000. The ten most intense ions 187 
were sequentially isolated and fragmented in the linear ion trap by collision induced 188 
dissociation (CID) at a target value of 10,000 or maximum ion time of 200 ms. A dynamic 189 
exclusion of ions previously sequenced within 45” was applied. All the singly charged and 190 
unassigned charge state ions were excluded from sequencing. Typical mass spectrometric 191 
conditions were: spray voltage, 2.3 kV; no sheath and auxiliary gas flow; heated capillary 192 
temperature, 275˚C; normalized CID collision energy 30% for MS2 in LTQ. The ion 193 
selection threshold was 10000 counts for MS2. An activation q = 0.25 and activation time 194 
of 30 ms were used (46). Raw data from the MS analysis was analysed using the 195 
streptococcal protein/peptide database (www.uniprot.org). In addition, de-novo peptide 196 
sequencing was performed on the MS/MS data for the AB39 peptide. All sequence tags 197 
obtained were compared to the producer strain draft genome using PEAKS Studio 7 198 
software (Bioinformatics Solutions, Waterloo, Canada) (47). 199 
Genomic DNA extraction and sequencing 200 
The genomic DNA of strain AB39 was extracted according to the instructions of the 201 
DNAasy Blood and Tissue Kit (Qiagen, UK). Sequencing reads were obtained by 202 
MicrobesNG, Birmingham University, UK (https://microbesng.uk/) using the Illumina HiSeq 203 
platform (Illumina Inc, USA).  Reads were trimmed using Trimmomatic (48) and their 204 
quality was evaluated using local scripts (Birmingham University, UK) in combination with 205 
multiple software tools, including  SAMtools (49), Bedtools (50) and  BWA-MEM (51). 206 
Assembly was accomplished by using the SPAdes de-novo assembly tool (52) with 207 
calculated quality determined via QUAST (53). Annotation and taxonomic identification 208 
were accompanied by using PROKKA prokaryotic (54) and Kraken (55) tools, respectively.  209 
Genome mining  210 
The draft genome was analysed in-silico using BAGEL-3 (56) and  antiSMASH-4.0 (57). 211 
For homology searches, amino acid sequences of all in-silico predicted peptides and/or 212 
their biosynthetic gene clusters (BGCs) were searched against relevant protein/peptide 213 
databases, including UniProt (57), BACTIBASE [http://bactibase.hammamilab.org] (58, 59), 214 
ProtBLAST/PSI-BLAST and the NCBI using the Basic Local Alignment Search Tool 215 
(BLAST) [https://blast.ncbi.nlm.nih.gov/Blast.cgi]. Amino acid sequences of in-silico 216 
predicted peptides were aligned with other similar/relevant peptides using the Jalview 217 
software multiple sequence alignment editor (60). Based on the percentage of amino acid 218 
identity, neighbour-joining trees were drawn using Jalview software to facilitate the 219 
determination of peptide relatedness. Moreover, whole putative BGCs were manually 220 
aligned with previously discovered ones, or using the genome comparison visualizer 221 
Easyfig (61). Sequences for the coding regions of genes in the nisin P cluster have been 222 
deposited to ENA under the accession numbers MN449418 to MN449428. 223 
Proteogenomic analysis and primary structure identification of nisin P 224 
Predicted masses, obtained from the purified active fractions via SDS-PAGE gel diffusion 225 
agar overlay and MS/MS fragmentation, were linked with bioinformatically obtained data in 226 
order to identify the genetic basis for production of the antibacterial activity produced by 227 
strain AP39. The primary structure of mature amino acid sequences of peptides was 228 
determined using the PepDraw tool [http://pepdraw.com/] to investigate the relatedness of 229 
NPs at the level of their primary structure. 230 
Stability towards hydrolytic enzymes, heat and pH 231 
Triplicate samples of purified AB39 peptide were treated with 1 mg/ml of α-amylase, α-232 
chymotrypsin, lipase, protease and trypsin (Sigma-Aldrich), whereas 10 mg/ml of 233 
proteinase K (Sigma-Aldrich) was used. All treated samples were serially diluted and all 234 
dilutions were assayed for their activity against M. luteus using the agar well diffusion 235 
assay. Based on the activity of the non-treated control sample, the percentage of retained 236 
activity was calculated.  237 
For heat stability, triplicate samples (~200 µl aliquots) of AB39 inhibitor were heated at 238 
80°C for 1-4 hours using a heating block or subjected to autoclaving at 121oC for 15 239 
minutes. In addition, AB39 peptide was incubated at a wide range of pH (3-8). The activity 240 
of treated samples was evaluated using the spot-on-lawn assay.  241 
Haemolytic activity  242 
The haemolytic activity of purified of nisin P towards sheep RBCs was assessed as 243 
formerly described (62) using AB39 peptide (1:10) serially diluted in PBS. PBS and 1% 244 
Triton™-100X (Sigma-Aldrich) were utilised as positive and negative controls, respectively. 245 
Haemolysis was assessed following incubation at 37°C for 60 minutes, after which time, 246 
samples were centrifuged at 2000 rpm for 10 minutes, and absorbance of the 247 
supernatants was measured at 560nm using a plate reader (BMG Labtech Ltd, Aylesbury, 248 
UK). The overall percentage haemolysis of the peptide was calculated using the following 249 
formula: % haemolysis = 100 (Absorbance of treated sample with the peptide – 250 
Absorbance of untreated samples) / (Absorbance of treated sample with Triton-X – 251 
Absorbance of untreated samples) (63). 252 
Toxicity study using selected cell lines 253 
Toxicity of the AB39 peptide was assessed towards Vero (Catalogue No. 85011422), 254 
MCF_7 (Catalogue No. 86012803) and HepG2 (Catalogue No. 85011430) cell lines, which 255 
were purchased from the European Collection of Authenticated Cell Cultures (ECACC) 256 
(Public Health England, Porton Down Salisbury, UK). Based on previous methods (39), 257 
nisin A [2.5% balance sodium chloride (Sigma-Aldrich)] was prepared and used as a 258 
positive control i due to its reported anticancer activity. Cells were recovered and grown 259 
according to the supplier’s guidelines, and growing cells (passage No: 8-16) were 260 
trypsinised before culture in 96 well tissue-culture plates (Grenier, Gloucestershire, UK) 261 
using phenol red free culture media, 1 X 10-4 cells/well seeding density in a volume of 90 262 
µl/well and using overnight incubation at 37°C with 5% CO2. Experiments were conducted 263 
using 10 µl/well from each prepared stock of concentrations of nisin A, AB39 compound 264 
and negative controls (10 µl of diluent plus 90 µl of each cell culture medium) with 265 
incubation at 37°C plus 5% CO2 for 96 hrs. Sodium phosphate (5mM; pH 2) was used as a 266 
diluent for nisin A (39), whereas the lyophilised AB39 peptide was dissolved in 0.01% 267 
acetic acid plus 0.2% Bovine serum albumin (BSA). Cell viability assay was assessed 268 
using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) 269 
(Promega, Southampton, UK) according to the manufacturer’s instructions with 270 
absorbance measured at 490nm. Obtained readings were analysed using the GraphPad 271 
Prism software (6.0) (64) and the IC50 of compounds towards cell lines was calculated. 272 
Cytopathic effects (CPEs) of treated and untreated cells were monitored using the 40X 273 
lens of an invented microscope and a digital microscopic camera (DCM-5-10, 5.0M pixels). 274 
 275 
Results 276 
Optimising the production and purification of the AB39 inhibitor 277 
A high yield of the inhibitor produced by strain AB39 (1600 AU/ml) was only achieved in 278 
BHI plus 10% FBS that was incubated statically and aerobically with 5 % CO2 for 6-10 279 
hours at 37°C. Extraction of the AB39 inhibitor was achieved using three successive steps 280 
of purification, in which the active fraction was eluted at 80% MeOH plus 0.01% TFA, 27.5% 281 
MeOH plus 0.01% TFA and 45% ACN plus 0.01% TFA or 13-14 minutes retention time 282 
(RT) via  Strata ® C18-E column, Sep-Pak® C18 cartridge and RP-HPLC, respectively. 283 
SDS-PAGE and gel overlay diffusion assay 284 
Purified AB39 inhibitor was run into an SDS-gel, in which observed bands possessed 285 
masses that ranged between ≥ 3 kDa and ≤ 7 kDa (Fig. 1). The gel diffusion agar overlay 286 
assay resulted in a zone of inhibition caused by a band within the same range, although 287 
the size of the zone appeared to be larger in the mass range between ≥ 3 kDa and ≤ 4 288 
kDa (Fig. 1).  289 
MS/MS analysis and de-novo sequencing 290 
Fragments generated during MS/MS analysis of AB39 active fractions mapped to multiple 291 
peptides not related to antimicrobial proteins. However, fragments that mapped to nisin U 292 
peptide, which is produced by S. uberis (65), were the most predominant (MS/MS count of 293 
66). In addition, de-novo peptide sequence analysis of the same fraction queried against 294 
the draft genome sequence of the producer led to the identification of a nisin U-like peptide, 295 
with 84% identity/coverage. 296 
Identification of the AB39 producing strain and genome mining for BCGs 297 
The AB39 producing strain was identified as S. gallolyticus (100% identity & coverage) 298 
based on the 16 S rRNA gene sequence (data not shown). In-silico analysis revealed two 299 
different putative bacteriocins. One of these showed 90.9% identity with nisin U (Fig. 2), 300 
indicating that this was the peptide that had been purified from S. gallolyticus strain. The 301 
other predicted peptide did not show any significant match to known antimicrobial peptides 302 
(AMPs). The amino acid sequence of the AB39 peptide aligned with all of published nisin 303 
variants and a neighbouring joining tree was generated (Fig. 3). 304 
Only when an extensive search in the literature was performed was it revealed that a 305 
previously described peptide had 100% identity with the AB39 purified peptide. During an 306 
in-silico study of the genome of a strain of S. gallolyticus, brief mention was made of a 307 
peptide designated nisin P, based on similarity to other nisin variants (66). As nisin P 308 
showed 100% identity with the AB39 peptide, the AB39 peptide has been called nisin P. 309 
Although the sequence has been previously reported, this is the first study to produce, 310 
purify and characterise the nisin P. 311 
Genetic organisation and annotation of the nisin P locus  312 
Based on the fact that genes required for the biosynthesis of potential bacteriocins are 313 
usually organised in close proximity to each other (67), genes upstream and downstream 314 
of the AB39 structural gene were manually annotated against relevant databases. This 315 
analysis led to the determination of the genetic organisation of all required genes (total n= 316 
11), with an indication of their potential function and the overall identity of each gene 317 
compared with the closest reported variant of this peptide (nisin U) (65) (Fig. 4 & Table 1). 318 
This comparison revealed synteny in the operons, but with a possible small inversion in 319 
the AB39 genome downstream of the structural gene, but in the non-coding region. 320 
Primary structure of nisin P, nisin A and nisin Z  321 
With respect to the relatedness/similarity between nisin A, nisin Z, nisin P and nisin U at 322 
the level of the primary structure of their mature sequences, it is apparent that nisin A and 323 
nisin Z share almost identical structures, as do nisin U and nisin P (Fig. 5). There are 324 
subtle differences between the structures of these two pairs of peptides. 325 
Physiochemical properties of nisin P 326 
Stability of nisin P towards hydrolytic enzymes [protease, trypsin, α-chymotrypsin, α-327 
amylase and lipase], pH and high temperature was determined. Based on the antimicrobial 328 
activity of a non-treated sample of nisin P (control) [2560 AU/ml] towards M. luteus, the 329 
activity of samples treated with protease, trypsin or α-chymotrypsin was reduced by about 330 
75%, while only 12.5% activity was retained in either α-amylase or lipase treated samples. 331 
In addition, although the exact percentage of retained activity of nisin P was not calculated, 332 
its activity was detected in a wide range of pH (3-8 pH) and temperatures [4-8oC for 4 333 
weeks, 80oC for 30 minutes and after autoclaving (121°C, 15 psi and for 15 minutes)].  334 
Spectrum of activity  335 
Nisin P showed antibacterial activity towards various type strains and clinical isolates of 336 
Gram positive drug resistant bacteria, whereas the tested species of Listeria and Bacillus, 337 
strains of Streptococcus agalactiae and Streptococcus anginosus and all Gram-negative 338 
species were not inhibited by nisin P (Table 2). 339 
Haemolytic activity towards sheep RBCs 340 
A double dilution of the highest concentration of nisin P obtained for active fractions, was 341 
the highest concentration of peptide able to be tested and this did not show any significant 342 
toxicity towards sheep enterocytes (0.32% lysis).  343 
Toxicity towards eukaryotic cell lines  344 
Nisin A showed significant activity towards MCF_7 and HepG2 cells, and slightly reduced 345 
toxicity towards Vero cells (Fig. 6). Therefore, the IC50 of nisin A is as follows: 362µg/ml, 346 
451µg/ml and 623µg/ml for MCF_7, HepG2 and Vero cells, respectively. In contrast, nisin 347 
P failed to show any significant activity towards these cell lines and the highest 348 
concentrations tested led to 15%, 5% and 20% reduction of MCF_7, HepG2 and Vero cell 349 
viability, respectively. Thus, it was not possible to determine the IC50 of nisin P towards 350 
these cells. Furthermore, all cells treated cells with nisin A showed obvious CPEs, 351 
including cell rounding, shrinking, detachment and/or vacuoles indicting their death, 352 
whereas nisin P treated cells, especially MCF_7 and HepG2, did not show any obvious 353 
CPE and appeared to be healthy cells compared to their controls. Nevertheless, there was 354 
a slight CPE (cell rounding) observed in Vero cells treated with nisin P (Fig. 7).  355 
 356 
Discussion  357 
Due to the growing worldwide crisis of AMR (3) as well as the low rate of discovery of new 358 
antibiotics, worldwide human health is under a serious threat (2, 68, 69). Thus, urgent 359 
action is needed to tackle the global crisis of AMR, including discovery of new antibacterial 360 
agents with unique modes of action. Various candidates exist, including the bacteriocins (3, 361 
14, 70-72). Certain bacteriocins (e.g nisin) possess a dual mode of action towards 362 
sensitive bacteria and this might explain the limited tendency for development of 363 
resistance to this class of AMPs (73, 74). The aim of this study was to characterise the 364 
inhibitor produced by a bacterium that was initially identified during a screen of various 365 
environmental and clinical bacterial strains. The focus of the active agent was determined 366 
towards a range of multidrug resistant (MDR) bacteria including MRSA, VRE and drug 367 
resistant S. pneumoniae. Here we describe the production, purification, physicochemical 368 
properties, genetic organisation and the toxicity of nisin P peptide, which has only been 369 
identified in silico in previous studies. 370 
A high yield of nisin P was obtained from S. gallolyticus between 6-10 hours, which 371 
correlated well with the time of incubation for the high level production of nisin A from 372 
Lactococcus lactis (75). Reduced activity of both peptides after 10 hours of incubation 373 
might be due to a reduction in the density of the producing cells, adsorption of the 374 
produced compound to the producing cells or potential proteolytic degradation (75, 76).  375 
SDS-gel analysis can be a useful tool for predicting the MW and purity level of a produced 376 
peptide (77). Therefore, the purest fraction containing nisin P was run into an SDS- gel 377 
and the MW of the observed bands fell within the range of the calculated theoretical MW of 378 
nisin P (3.133 KDa). In addition, the inhibitory zone that was observed towards M. luteus 379 
using the gel diffusion overlay assay corresponded to bands within the same MW range. 380 
Furthermore, MS/MS analysis of the AB39 active fraction from HPLC generated multiple 381 
hits (total n=114) in the UniProt database, but the hit with the highest MS/MS count (n=66) 382 
mapped to nisin U (65). These findings support the suggestion that the purified AB39 383 
compound is closely related to nisin U.  384 
Bioinformatic analysis that was conducted on the draft genome of S. gallolyticus, revealed 385 
nisin P and all required genes for its biosynthesis. BGCs encoding bacteriocins should 386 
encompass all required genes for the biosynthesis and production of inhibitors (e.g self-387 
immunity, regulation and exportation), and these are usually found in close proximity to the 388 
structural gene (78, 79). Genes of the nisin P cluster were syntenic with those within the 389 
nisin U cluster with 94.6% and 82.1% maximum and minimum identity, respectively. The 390 
organisation of these clusters is unlike that of the genes encoding nisin A (80). Based on 391 
overall homology and relatedness of the AB39 inhibitor (nisin P) to sequences for other 392 
nisin variants including nisin A (81), nisin Z (82), nisin Q (83), nisin U (65), nisinF (84), 393 
nisin H (80) and nisin O (85), it appeared to be a new variant of nisin U.  394 
The AB39 peptide showed 100% identity to a putative nisin variant predicted from the 395 
genome of a strain of S. gallolyticus, which was called nisin P (66). Therefore, the AB39 396 
peptide has been named nisin P, to avoid any potential ambiguity. In addition, in the study 397 
by Zhang and colleagues (65), only the structural gene was reported and here the entire 398 
operon has been characterised. Furthermore, in our study, optimised laboratory production, 399 
physicochemical analysis, antibacterial and anticancer activity determination and toxicity 400 
testing of nisin P have been conducted, for the first time. 401 
The antimicrobial activity of nisin P was reduced by 75% following treatment with protease, 402 
trypsin or α-chymotrypsin. This finding, as well the availability of three potential trypsin 403 
cleavage sites within nisin P sequence confirm its proteinaceous nature (18, 21, 22). 404 
Additionally, nisin P was found to be more sensitive to α-amylase and lipase enzymes 405 
leading to about 12.5% retained activity and this might suggest the availability of 406 
polysaccharide and lipid moieties within nisin P (41). Furthermore, although the 407 
percentage of retained activity of nisin P was not calculated, its activity was detected at a 408 
wide range of pH (3-8 pH) and temperatures. The observed stability of nisin P under these 409 
conditions correlates with that reported for nisin A (86), emphasising their potential 410 
effectiveness for use in various environments. 411 
Nisin P displayed very limited levels of toxicity towards sheep RBCs at the highest 412 
concentration tested. Despite the fact that nisin A is approved by the USA FDA as a food 413 
preservative and it has been used globally for more than five decades (75, 80), further in 414 
vitro and in vivo evaluation of nisin P toxicity is required. Nevertheless, the low levels of 415 
haemolysis might support speculation about a promising potential for use of nisin P to treat 416 
bacterial infections caused by drug resistant bacteria in humans and/or animals.  417 
Nisin P exhibited biological activity towards various genera of Gram positive bacteria, 418 
including species of Micrococcus, Streptococcus, Staphylococcus and Clostridium. 419 
However, nisin P failed to inhibit the growth of all tested species of Bacillus and Listeria, 420 
and strains of S. anginosus and S. agalactiae. It was not active against Gram-negative 421 
bacteria. Nisin A is known for its activity towards species of Bacillus, Listeria, 422 
Streptococcus and Staphylococcus (75). The nature of the resistance of some 423 
streptococcal indicators to nisin P is yet to be explained. Nevertheless, based on the 424 
reported biological activity towards bacterial species, nisin A and nisin Z are found to be 425 
the most effective forms of nisin to date, and, thus, more limited activity from other variants 426 
would be expected, especially in Streptococcal derived nisins (e.g nisin U) (80, 86). This 427 
might be due to the increased variations within the amino acid sequences of Streptococcal 428 
nisins (nisin U, nisin H and nisin P) compared to lactococcal nisins (nisin A, nisin Z, nisin F, 429 
nisin Q) and the increase in the variation might be claimed to be inversely linked with 430 
biological activity (65, 80). 431 
Nisin A and nisin Z have been claimed to be the most effective forms of nisin variants and 432 
their activity towards cancer cells including MCF_7 and HepG2 has been described (36, 433 
37, 39, 86). Therefore, toxicity of nisin P towards Vero, MCF_7 and HepG2 cells was 434 
evaluated to reveal whether or not selective activity towards cancer cells exists. Nisin A 435 
showed significant toxicity, which was defined by at least 50% reduction of viable cells, 436 
towards cancer and Vero cells. The toxicity of nisin A appeared to be less towards Vero 437 
cells than MCF_7 and HepG2 cells, as has been described previously (39) and this might 438 
indicate its selectivity towards malignancies and its potential promise as a cancer 439 
therapeutic drug. In contrast, all tested concentrations of nisin P did not show any 440 
significant toxicity towards tumour and Vero cells. Images of Vero, MCF_7 and HepG2 441 
cells treated with nisin A showed clear CPE, while there was either no or very little CPE in 442 
cells treated with nisin P. Nisin P was only marginally more toxic towards Vero cells than 443 
MCF_7 cells and HepG2 cells at 2500 µg /ml after 96 hours of exposure. However, 444 
differences in activity between cell lines was not statistically significant, indicating that nisin 445 
P does not possess any selective activity towards the particular cancer cells tested here. 446 
This might limit its potential use as a drug for treating tumour cells, though activity against 447 
additional cell lines could be tested. Nevertheless, due to the limited toxicity of nisin P 448 
towards Vero cells compared to nisin A, it still holds promise for potential use to treat 449 
bacterial infections caused by certain species within humans or/and animals. The 450 
variations within the amino acid sequences between nisin P and nisin A might be the only 451 
reason behind the distinct toxicity profile of nisin P towards bacterial, Vero, MCF_7 and 452 
HepG2 cells, which is unlike that described for nisin A (36, 37, 39, 80, 86). This is because 453 
the determined primary structure of nisin A and nisin Z are almost identical and distinct 454 
from that of nisin U and nisin P, which may give insight into experiments to engineer nisin 455 
to enhance antibacterial or anti-cancer activity. 456 
 457 
Conclusion  458 
The first successful production, purification and characterisation of the nisin P peptide has 459 
been achieved from a strain of S. gallolyticus subsp. pasteurianus in this study. Nisin P 460 
showed antibacterial activity towards MDR bacteria including MRSA, VRE and drug 461 
resistant S. pneumoniae with very limited toxicity towards sheep erythrocytes and 462 
eukaryotic cells [Vero cells]. Consequently, nisin P might hold a promise to treat or prevent 463 
bacterial infections caused by these organisms within humans and animals.  464 
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707 
Figure legends and table headings 708 
  709 
Figure 1. Images of an SDS-gel ladder [A], SDS-gel [B] and gel diffusion overlay of the 710 
purified AB39 peptide [C]. Red dashed lines indicate the inhibitory zone caused by the 711 
peptide and its range of mass (3-7 kDa).  712 
Figure 2. [A] Biosynthetic gene cluster (BCG) predicted by the BAGEL-3 mining tool from 713 
the draft genome of S. gallolyticus (AB39 strain), in which all genes required for the 714 
biosynthesis of the predicted peptide are present, as well as the structural gene (green). [B] 715 
The amino acid sequences of the putative peptide (AB39) showed 90.9% identity with nisin 716 
U that was described in S. uberis (65). 717 
Figure 3. [A] Alignment the amino acid sequences of the AB39 peptide with all reported 718 
nisin variants [B] neighbouring joining tree generated for all aligned sequences to 719 
determine their relatedness. 720 
Figure 4. Genetic organisation of all genes (total n=11) that are required for the 721 
biosynthesis of nisin P, and the amino acid sequences of all genes were aligned with those 722 
encoding the nisin U peptide using Easyfig. The homology is a colour gradient, in which 723 
100% and 82% homology are indicated by the blue and red colours, respectively. Note: 724 
nspP = protease (cleavage) gene, nspR & nspK = regulation genes, nspF, nspE, nspG & 725 
nspI = immunity genes, nspB & nspC = genes involved in the post-translational 726 
modifications (PTMs) and nspT = transportation gene. 727 
Figure 5. Primary structure of nisin A, nisin Z, nisin U and nisin P, as determined using the 728 
PepDraw tool [http://pepdraw.com/].   729 
Figure 6. Toxicity of nisin P [A] and nisin A [B] towards breast adenocarcinoma (MCF_7), 730 
liver hepatocellular carcinoma (HepG2) and monkey kidney epithelial cells (Vero cells) 731 
using different concentrations of these peptides and 96 hours of exposure. ‘n.s’ = not 732 
statistically significant. 733 
Figure 7. Images of treated eukaryotic cells [breast adenocarcinoma (MCF_7), liver 734 
hepatocellular carcinoma (HepG2) and monkey kidney epithelial cells (Vero cells)] with 735 
nisin A or nisin P (2500 µg/ml and 96 hours exposure) and non-treated cells (controls).  736 
Table 1. Genes that are likely to be required for the biosynthesis of the AB39 peptide 737 
(nisin P) and their predicted functions, based on their synteny and homology with genes 738 
encoding the nisin U peptide (65). 739 
Table 2. Spectrum of activity of purified nisin P peptide towards various Gram positive and 740 
-negative indicator strains. The inhibitory zones were measured in an arbitrary unit (AU), in 741 
which ‘+’ is the smallest zone while ‘++++’ was designated for the largest zone. Note: - = 742 
resistance of indicator/s, NCTC = National Collection of Type Cultures, UoP = University of 743 
Plymouth, VRE = Vancomycin-resistant Enterococcus, MRSA = Methicillin-resistant 744 
Staphylococcus aureus, MSSA = Methicillin-sensitive Staphylococcus aureus and PR = 745 
penicillin resistant.  746 
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